Marc Ballas

1.3k total citations
46 papers, 905 citations indexed

About

Marc Ballas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Marc Ballas has authored 46 papers receiving a total of 905 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Marc Ballas's work include Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (14 papers) and Lung Cancer Research Studies (10 papers). Marc Ballas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Lung Cancer Treatments and Mutations (14 papers) and Lung Cancer Research Studies (10 papers). Marc Ballas collaborates with scholars based in United States, France and Spain. Marc Ballas's co-authors include Jill Walker, Anita Midha, Yiduo Zhang, Craig Barker, Mohd Kashif Siddiqui, Robert S. Brody, Kelvin Shi, Jean‐Charles Soria, David Planchard and Young‐Chul Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Marc Ballas

44 papers receiving 894 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Ballas United States	14	554	336	254	144	121	46	905
Malaka Ameratunga Australia	14	375 0.7×	282 0.8×	268 1.1×	114 0.8×	60 0.5×	45	824
Stephanie Du Four Belgium	15	435 0.8×	231 0.7×	287 1.1×	264 1.8×	67 0.6×	34	834
Suthee Rapisuwon United States	11	683 1.2×	158 0.5×	329 1.3×	246 1.7×	59 0.5×	30	997
Solenn Brosseau France	15	436 0.8×	409 1.2×	140 0.6×	72 0.5×	45 0.4×	53	711
Ladan Fazlollahi United States	9	324 0.6×	269 0.8×	395 1.6×	96 0.7×	108 0.9×	21	1.2k
Bin Meng China	18	334 0.6×	186 0.6×	245 1.0×	136 0.9×	59 0.5×	62	814
Tommaso D’Antuono Italy	14	358 0.6×	308 0.9×	187 0.7×	174 1.2×	30 0.2×	21	717
Valérie Méresse France	13	335 0.6×	103 0.3×	314 1.2×	117 0.8×	133 1.1×	23	830
Claudia Le United States	5	465 0.8×	442 1.3×	386 1.5×	189 1.3×	123 1.0×	5	1.1k
Heather M. Shaw United Kingdom	13	352 0.6×	132 0.4×	349 1.4×	93 0.6×	39 0.3×	34	725

Countries citing papers authored by Marc Ballas

Since Specialization

Citations

This map shows the geographic impact of Marc Ballas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Ballas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Ballas more than expected).

Fields of papers citing papers by Marc Ballas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Ballas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Ballas. The network helps show where Marc Ballas may publish in the future.

Co-authorship network of co-authors of Marc Ballas

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Ballas. A scholar is included among the top collaborators of Marc Ballas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Ballas. Marc Ballas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maio, Michele, Víctor Moreno, Juan Martín-Liberal, et al.. (2025). First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011475–e011475. 1 indexed citations

Hilton, John, Patrick A. Ott, Aaron R. Hansen, et al.. (2024). INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunology Immunotherapy. 73(3). 44–44. 10 indexed citations

Turner, David C., Xiaowei Wang, Rik de Greef, et al.. (2023). Model‐based meta‐analysis of non‐small cell lung cancer with standard of care PD‐1 inhibitors and chemotherapy for early development decision making. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1751–1763. 7 indexed citations

Callander, Natalie S., Vincent Ribrag, Paul G. Richardson, et al.. (2021). DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 138(Supplement 1). 897–897. 11 indexed citations

Angevin, Eric, Stefanie L. Groenland, Todd M. Bauer, et al.. (2020). 11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study. Annals of Oncology. 31. S3–S3. 2 indexed citations

Ballas, Marc, et al.. (2020). 951P The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis. Annals of Oncology. 31. S675–S676.

Tourneau, C. Le, Danny Rischin, Stefanie L. Groenland, et al.. (2020). 1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 31. S1–S1. 3 indexed citations

Bauer, Todd M., Benjamin Besse, Alex Martínez‐Martí, et al.. (2019). Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. Journal of Thoracic Oncology. 14(10). 1828–1838. 61 indexed citations

Komiya, Takefumi, Regan M. Memmott, Gideon M. Blumenthal, et al.. (2019). A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. Translational Lung Cancer Research. 8(3). 247–257. 12 indexed citations

10.

Richardson, Paul G., Swethajit Biswas, Beata Holkova, et al.. (2019). Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 1857–1857. 7 indexed citations

11.

Maio, Michele, Stefanie L. Groenland, Todd M. Bauer, et al.. (2019). Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study. Annals of Oncology. 30. v793–v793. 2 indexed citations

12.

Brody, Robert S., Yiduo Zhang, Marc Ballas, et al.. (2017). PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 112. 200–215. 234 indexed citations

13.

Planchard, David, Takashi Yokoi, Michael McCleod, et al.. (2016). A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. Clinical Lung Cancer. 17(3). 232–236.e1. 110 indexed citations

14.

Camidge, D. Ross, Eamon M. Berge, Robert C. Doebele, et al.. (2014). A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(10). 1532–1539. 41 indexed citations

15.

Karajannis, Matthias A., Geneviève Legault, Mari Hagiwara, et al.. (2012). Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. 14(9). 1163–1170. 114 indexed citations

16.

Gitlitz, Barbara J., Denice Tsao‐Wei, Susan Groshen, et al.. (2011). A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium Trial. Journal of Thoracic Oncology. 7(3). 574–578. 28 indexed citations

17.

Donington, Jessica, Chi Wan Koo, & Marc Ballas. (2011). Novel Therapies for Non-Small Cell Lung Cancer. Journal of Thoracic Imaging. 26(2). 175–185. 13 indexed citations

18.

Blumenthal, Gideon M., Marc Ballas, Michael E. Ernst, et al.. (2010). A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC.. Journal of Clinical Oncology. 28(15_suppl). 7600–7600. 5 indexed citations

19.

Ballas, Marc, et al.. (2008). Malignant Pleural Mesothelioma—A Current Review. 4(1). 60–60. 1 indexed citations

20.

LoPiccolo, Jaclyn, Marc Ballas, & Phillip A. Dennis. (2007). PTEN hamartomatous tumor syndromes (PHTS): Rare syndromes with great relevance to common cancers and targeted drug development. Critical Reviews in Oncology/Hematology. 63(3). 203–214. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact